T 1844/17 of 25.06.2021

European Case Law Identifier: ECLI:EP:BA:2021:T184417.20210625
Date of decision: 25 June 2021
Case number: T 1844/17
Petition for review of: -
Application number: 11730112.7
IPC class: A61K 31/517 A61K 45/06 A61K 39/00 C07K 16/28 A61P 35/00 C07K 16/32 A61K 39/395 C07K 16/30 A61K 31/337
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
Applicant name: Merrimack Pharmaceuticals, Inc.
Opponent name: Daiichi Sankyo Co Ltd
Board: 3.3.01
Headnote: -
Relevant legal provisions: European Patent Convention Art 113(2)
Keywords: Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked
Catchword: -
Cited cases: T 0073/84
Citing cases: T 1936/18 T 3007/18 T 0320/19 T 0411/20 T 2210/21 T 1289/23 T 0466/24

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.